DDInter890 DDInter1376
Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8. Due to these modifications, it presents a very high potency and comparable side effect profile to the parent compound. Even though hydromorphone does not present a 6-hydroxyl group, it is categorized under the family of phenanthrenes and it is considered a chemical under the schedule II (medical purposes with high addiction potential). The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Hydromorphone {u} (Compound) resembles {v} (Compound) Ethylmorphine
Hydromorphone {u} (Compound) resembles {v} (Compound) Oxycodone
Hydromorphone {u} may lead to a major life threatening interaction when taken with {v} Morphine
Hydromorphone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dextromethorphan
Hydromorphone {u} (Compound) binds {v} (Gene) CYP2D6
Hydromorphone {u} (Compound) is included by {v} (Pharmacologic Class) Full Opioid Agonists
Hydromorphone {u} (Compound) causes {v} (Side Effect) Syncope
Hydromorphone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trospium
Hydromorphone {u} may lead to a major life threatening interaction when taken with {v} Alvimopan
Hydromorphone {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naloxone
Hydromorphone (Compound) resembles Ethylmorphine (Compound)
Hydromorphone (Compound) resembles Oxycodone (Compound)
Hydromorphone may lead to a major life threatening interaction when taken with Morphine
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan
Hydromorphone (Compound) binds CYP2D6 (Gene)
Hydromorphone (Compound) is included by Full Opioid Agonists (Pharmacologic Class)
Hydromorphone (Compound) causes Syncope (Side Effect)
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Trospium
Hydromorphone may lead to a major life threatening interaction when taken with Alvimopan
Hydromorphone (Compound) resembles Naloxone (Compound) and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Naloxone